This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TearLab Corporation To Release Q3-10 Financial Results On November 11, 2010

SAN DIEGO, Nov. 3, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the third quarter before the market opens on Thursday, November 11, 2010.

TearLab is pleased to invite all interested parties to participate in a conference call during which time financial results will be discussed. The call will be held on November 11, 2010, at 8:30a.m. Eastern Standard Time at 877-303-6310 (within the United States and Canada).

 Date:	November 11, 2010
 Time:	8:30 AM ET

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):

 Telephone:     (877) 303-6310

For those wishing to listen to a recording of the call via telephone, a replay will be made available by 11:30am EST after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (800) 642-1687 or (706) 645-9291 and enter reservation # 18561749 when prompted.

About OccuLogix, Inc. dba TearLab Corporation

OccuLogix dba TearLab Corporation ( develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB.' TearLab received the CE Mark for its TearLab(TM) Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 20 countries including the US.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding the growth of the market for dry eye disease products, the impact of our product on the management of affected patients, and our intention to seek CLIA Waiver. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
CONTACT:  Kilmer Lucas Inc.
          Stephen Kilmer (President)
            905 690-2400 Ext.21
          Leonard Zehr (Managing Director)
            905 690 2400 Ext.41

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs